TabsDetailsBasic DetailsDate Posted: Tuesday, October 25, 2016Status: CompleteMedical Product: Strattera, amphetamine, methylphenidateHealth Outcome(s): heart failureDescription: Modular program-based one-time assessment of heart failure diagnoses following new attention deficit hyperactivity disorder (ADHD) medication use. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2000 through March 3, 2016. Modular programs are adaptable standardized programs. Results were generated using the Cohort Identification and Descriptive Analysis (CIDA) tool, click here for more information. Queries were distributed in March 2016. These reports include data from 15 Data Partners.If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@sentinelsystem.org.The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Please read the disclaimer. Read More Deliverables (1)Sentinel Modular Program Report: ADHD Medications and Heart FailureAdditional InformationAdditional DetailsFDA Center: CDERTime Period: 2000 - 2016Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study